ABBOTT PARK, Ill.& SAN DIEGO---- Abbott, the global health care company, and Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced that the t ...

Abbott’s 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care Provided by Accesswire Feb 5, 2025 1:30am ...

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott ...

“This is a win for people with diabetes, offering more people world-leading Libre technology,” said Jared Watkin, executive vice president of Abbott’s diabetes care business, in a statement.

The heat of the summer season brings a few more challenges for children living with diabetes. An expert speaks about how the ...

Abbott Laboratories (NYSE:ABT) recently introduced the FreeStyle Libre 3 Plus in Canada, marking an advancement in diabetes management technology with its small, sensor-based glucose monitoring ...

Abbott narrowed its adjusted earnings for 2023 on Wednesday, projecting a range of $4.42 to $4.46 a share, compared to the earlier range of $4.30 to $4.50. Abbott’s stock was up 3.2% Wednesday ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our ...

The company revolutionized diabetes care 10 years ago with its world-leading Libre continuous glucose monitoring portfolio, which today is used by 7 million people in more than 60 countries. 4 ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that ...